Special Issue

New Insights in Gastric, Colorectal, and Pancreatic Cancer

Message from the Guest Editor

Gastric, colorectal and pancreatic cancer represent the most important malignant neoplasms of the digestive system in terms of frequency and clinical importance. Advances in conservative treatment are especially impressive. For example, immunotherapy of these cancers alone or in combination with systemic chemotherapy is the therapeutic strategy of the present and the future. This Special Issue focuses on the recent data regarding these three neoplasms, intending to cover among others, the following topics:

- Mechanisms of carcinogenesis;
- Tumor cell biology;
- Hereditary gastric, CRC and pancreatic cancer;
- Polyps (gastric and colorectal);
- Biomarkers (diagnostic and prognostic);
- Tumor staging;
- Imaging techniques;
- Animal models;
- Stem cells;
- Advances in chemotherapy;
- Immunotherapy in gastric and pancreatic cancer, alone or in combination;
- Advances in the treatment of metastatic pancreatic, CRC and gastric cancer.

We aspire for this Special Issue to cover at least part of the wide spectrum of the etiologies, diagnoses and treatments of these neoplasms, always in the light of a multidisciplinary approach.

Guest Editor

Dr. John K. Triantafillidis
Director IBD Unit, Metropolitan General Hospital, 15562 Holargos, Greece

Deadline for manuscript submissions

closed (31 March 2026)

Biomedicines

an Open Access Journal by MDPI

Impact Factor 4.5
CiteScore 7.8
Indexed in PubMed

mdpi.com/si/197247

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines

Biomedicines

an Open Access Journal by MDPI

Impact Factor 4.5
CiteScore 7.8
Indexed in PubMed

mdpi.com/journal/biomedicines

About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni
1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.2 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2026).